Personalised vaccines given only when the blood test turns positive
Custom cancer vaccines take weeks to make and work best when there is very little disease. Making one at surgery and giving it when a blood test turns positive matches both facts.
An individualised mRNA neoantigen vaccine produced immune responses and prolonged recurrence-free survival in a randomised phase 2 in ctDNA-positive resected pancreatic and colorectal cohorts, and adjuvant melanoma data support the setting. Manufacturing time is the practical constraint, which a manufacture-at-surgery, deploy-on-ctDNA-positivity design resolves, and it concentrates cost on the minority who will relapse.
- Dormant cells and minimal residual disease · After a 'successful' treatment, cells can sleep for years then relapse. We can barely detect them and cannot target them.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
Pages like this
not linked directly; found by shared links- IdeaPersonalised cancer vaccines at commodity cost through fully automated manufacturing
Shares BioNTech, Autogene cevumeran, Moderna, Intismeran autogene.
- InstitutionUniversity Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz
Shares BioNTech, Autogene cevumeran, Neoantigen, Personalised neoantigen (mRNA) vaccines.
- Key paperRojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer
Shares BioNTech, Autogene cevumeran, Intismeran autogene, Neoantigen.
- PairingPersonalised neoantigen vaccine + PD-1 blockade
Shares Autogene cevumeran, Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Melanoma.
- IdeaVaccines aimed only at mutations shared by every tumour cell
Shares BioNTech, Moderna, Neoantigen, Personalised neoantigen (mRNA) vaccines.
- IdeaWhat makes a neoantigen actually immunogenic?
Shares Autogene cevumeran, Intismeran autogene, Neoantigen, Personalised neoantigen (mRNA) vaccines.
- Key paperKEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery
Shares Moderna, Intismeran autogene, Neoantigen, Personalised neoantigen (mRNA) vaccines.
- TechnologySelf-amplifying and circular RNA therapeutics
Shares BioNTech, Moderna, Personalised neoantigen (mRNA) vaccines.